Age & purpose verification
PeptideSeed supplies research compounds for in-vitro laboratory use only. By entering this site you confirm:
Research use only. Not for human or veterinary consumption. Full terms of supply
PT-141, Melanotan II and KPV all trace back to alpha-MSH. How one shared receptor family produces three structurally distinct research reagents.
All three of these sequences trace back to alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that is the parent molecule for the melanocortin research field. PT-141 and Melanotan II are both cyclic analogues built around alpha-MSH's core receptor-binding motif; KPV is the native hormone's own C-terminal tripeptide fragment, taken as-is rather than modified.
Sharing an ancestor does not make the three interchangeable. Each is studied for a distinct reason, and the structural differences between them - not their common origin - are what determine which one a given protocol calls for.
Alpha-MSH and its analogues act at the melanocortin receptors, a family of five G-protein-coupled receptor subtypes (MC1R through MC5R) distributed across different tissues and associated with different physiological roles in the literature. A compound's receptor subtype selectivity profile - which of the five it engages and how strongly - is what actually differentiates one melanocortin analogue's research relevance from another's, more than gross structural similarity does.
This is why PT-141 and Melanotan II, despite differing by a single chemical modification, are studied as distinct compounds: that one modification is enough to shift the subtype selectivity profile meaningfully.
Melanotan II is a cyclic heptapeptide closed by a lactam bridge between its aspartate and lysine side chains, C-terminally amidated, and acts as a non-selective melanocortin receptor agonist active across several of the five subtypes. That non-selectivity is a defining feature of the molecule and the reason it is used in broad-spectrum melanocortin studies rather than subtype-specific ones.
Its tryptophan residue and conjugated ring system make it one of the more light-sensitive sequences in the catalogue, on the same order as GHK-Cu and DSIP; it ships in opaque packaging and should stay there through handling.
PT-141, also catalogued under its non-proprietary name bremelanotide, shares Melanotan II's cyclic heptapeptide core but differs at the C-terminus: PT-141 carries a free carboxylic acid where Melanotan II is amidated. It is, structurally, a metabolite of Melanotan II.
That single difference in terminal chemistry shifts the receptor subtype selectivity profile enough that the two are treated as separate research reagents rather than variants of one compound. Like Melanotan II, PT-141 retains the tryptophan residue and needs the same light protection.
KPV is unmodified - it is simply residues 11 through 13 of native alpha-MSH, supplied as the bare tripeptide rather than as a cyclized, amidated analogue. At three residues it is the shortest sequence in the entire catalogue and the only one of these three that is not a designed synthetic analogue.
The literature on KPV specifically notes activity reported independent of classical melanocortin receptor engagement, which sets it apart in research interest from PT-141 and Melanotan II even though all three share the same parent hormone. It also carries no chromophore and gives a colourless solution, unlike the other two.
Despite the shared lineage, substituting one of these three for another in a protocol changes what is actually being studied - non-selective broad melanocortin agonism for Melanotan II, a shifted subtype profile for PT-141, and a short fragment associated with effects reported outside classical receptor engagement for KPV.
Any protocol referencing 'alpha-MSH analogues' generically should specify which of the three is meant, since the differences between them are the point rather than an incidental detail.
This guide is general laboratory reference material relating to the handling of research compounds. It is not medical, veterinary or clinical guidance, and it does not describe or imply any use in humans or animals. All PeptideSeed material is supplied for in-vitro laboratory research only — see the terms of supply.